After Doubling in Six Montsh, Is it Too Late to Buy Hims & Hers Stock?

Parkev discusses Hims & Hers, a rapidly growing healthcare company that achieved over $753 million in revenue in its most recent quarter, a 40% year-over-year increase, and now boasts over 3 million subscribers. The company has expanded internationally into three markets, each approaching a $100 million revenue run rate, thanks to its acquisition of Eucalyptus. Parkev highlights the company's aggressive approach in a "gray area" of product sales, leading to litigation and regulatory difficulties, which contributes to its significant stock price volatility, often moving two to three times more than the S&P 500. He emphasizes that this stock is exclusively for investors with a high-risk tolerance who are not unsettled by volatility.

Parkev sees Hims & Hers as an innovator in the healthcare industry, addressing long-standing customer complaints about service and cost by offering value outside the traditional system. The company has generated $2.6 billion in revenue over the last 12 months and is utilizing artificial intelligence to improve customer experience and reduce service costs. While its operating profit margins have been highly volatile, fluctuating from -45% to +15% and back to flat/negative levels, Parkev expects this trend to continue for a few years as the company navigates the industry and establishes its position before focusing on efficiencies.